Consultation outcome

Review of temporary provisions in the Human Medicines Regulations 2012 to support influenza and COVID-19 vaccination campaigns

This was published under the 2019 to 2022 Johnson Conservative government
This consultation has concluded

Read the full outcome

Detail of outcome

From 8 to 29 December 2021, the聽Secretary of State for Health and Social Care in relation to Great Britain, and in conjunction with the Minister of Health in Northern Ireland, in relation to Northern Ireland,聽consulted on certain temporary provisions in the Human Medicines Regulations 2012 (HMRs) to support influenza and COVID-19 vaccination campaigns.

皇冠体育app response confirms that priority will be given to the implementation of those provisions that will lapse on 1 April 2022, with the remaining proposals to be taken forward in subsequent tranches.


Original consultation

Summary

We would like your views on a review of temporary provisions in the Human Medicines Regulations to support influenza and COVID-19 vaccination campaigns.

This consultation ran from
to

Consultation description

皇冠体育app Human Medicines Regulations 2012 (HMRs) were amended in the final quarter of 2020 to add flexibility to some of the normal rules that would ordinarily govern vaccines and their supply to patients, in light of COVID-19. 皇冠体育app changes were to facilitate the mass vaccination campaigns that have been taking place against both COVID-19 and seasonal influenza in the UK. 皇冠体育appse provisions remain in force until 1 April 2022 to support COVID-19 and seasonal influenza vaccinations.

Action is needed to determine if the provisions should be made permanent, extended for a further limited period or allowed to lapse. 皇冠体育app Secretary of State, in conjunction with the Minister of Health in Northern Ireland, is seeking views on these proposals. 皇冠体育app suggested changes to the HMRs will help to ensure the NHS continues to have the added flexibility it requires to operate any necessary mass vaccination programmes for COVID-19 and influenza.

We understand that the NHS has already used the full range of options available to them as provided by the HMRs to deliver vaccines safely and effectively at the pace and scale required.

In the interests of pandemic preparedness, we are also seeking views on whether to retain these provisions so that they may apply to any future pandemic.

Documents

Updates to this page

Published 8 December 2021
Last updated 25 January 2022 show all updates
  1. Consultation response published.

  2. First published.

Sign up for emails or print this page